4503 — Astellas Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapNeutral

Annual income statement for Astellas Pharma, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,300,843	1,249,528	1,296,163	1,518,619	1,603,672
Cost of Revenue
Gross Profit	1,024,104	1,003,465	1,043,154	1,230,266	1,311,187
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,056,852	1,102,919	1,135,393	1,390,597	1,578,407
Operating Profit	243,991	146,609	160,770	128,022	25,265
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	245,350	145,324	156,886	132,361	24,969
Provision for Income Taxes
Net Income After Taxes	195,411	120,590	124,086	98,714	17,045
Net Income Before Extraordinary Items
Net Income	195,411	120,590	124,086	98,714	17,045
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	195,411	120,589	124,086	98,714	17,045
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	110	111	95.3	92.8	45.6
Dividends per Share